How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?

dc.contributor.authorYener, Neslihan Parmak
dc.contributor.authorKılınçel, Oğuzhan
dc.contributor.authorGündüz, Cem
dc.contributor.buuauthorGündüz, Gamze Uçan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-6661-2021tr_TR
dc.contributor.scopusid57204236887tr_TR
dc.date.accessioned2023-11-03T09:59:12Z
dc.date.available2023-11-03T09:59:12Z
dc.date.issued2018-05
dc.description.abstractPurpose: To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. Methods: This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. Results: The median IOP was significantly lower in patients using antidepressants [16.0 (11.0-21.0) mmHg] than the control group [17.5 (12.0-21.0) mmHg] (P=0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29-5.60) mm] than the control group [2.95 (2.00-4.40) mm] (P=0.000). In the study group, PD was also significantly larger in patients using SNRIs for 6 months [3.67 (2.38-5.08) mm] than <6 months [3.31 (2.29-5.60) mm] (P=0.000). The median ACD was significantly lower in patients using antidepressants for 6 months [3.21 (2.52-4.06) mm] than the control group [3.44 (2.63-4.29) mm] (P=0.000). ACAs were measured between 25 degrees and 55 degrees by Scheimpflug imaging. Conclusions: Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage.en_US
dc.identifier.citationGündüz, G. U. vd. (2018). ''How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?''. Journal of Ocular Pharmacology and Therapeutics, 34(4), 354-359.en_US
dc.identifier.endpage359tr_TR
dc.identifier.issn1080-7683
dc.identifier.issn1557-7732
dc.identifier.issue4tr_TR
dc.identifier.pubmed29446702tr_TR
dc.identifier.scopus2-s2.0-85046906129tr_TR
dc.identifier.startpage354tr_TR
dc.identifier.urihttps://doi.org/10.1089/jop.2017.0133
dc.identifier.urihttps://www.liebertpub.com/doi/10.1089/jop.2017.0133
dc.identifier.urihttp://hdl.handle.net/11452/34774
dc.identifier.volume34tr_TR
dc.identifier.wos000425183200001tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherMary Ann Lieberten_US
dc.relation.collaborationSanayitr_TR
dc.relation.journalJournal of Ocular Pharmacology and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOphthalmologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectAnterior segment parametersen_US
dc.subjectIntraocular pressureen_US
dc.subjectSerotonin noradrenaline reuptake inhibitorsen_US
dc.subjectAngle-closure glaucomaen_US
dc.subjectVenlafaxineen_US
dc.subjectMechanismsen_US
dc.subjectExpressionen_US
dc.subjectPotenten_US
dc.subjectAgentsen_US
dc.subject.emtreeDuloxetineen_US
dc.subject.emtreeSerotonin noradrenalin reuptake inhibitoren_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeDuloxetineen_US
dc.subject.emtreeSerotonin noradrenalin reuptake inhibitoren_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAnterior chamber volumeen_US
dc.subject.emtreeAnterior eye chamber angleen_US
dc.subject.emtreeAnterior eye chamber depthen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCentral corneal thicknessen_US
dc.subject.emtreeClinical evaluationen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCross-sectional studyen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGonioscopyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeIntraocular pressureen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOphthalmologyen_US
dc.subject.emtreePsychopharmacotherapyen_US
dc.subject.emtreePupilen_US
dc.subject.emtreeVisual system parametersen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeIntraocular pressureen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeYoung adulten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntidepressive agentsen_US
dc.subject.meshCross-sectional studiesen_US
dc.subject.meshDepressive disorder, majoren_US
dc.subject.meshDuloxetine hydrochlorideen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIntraocular pressureen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshSerotonin and noradrenaline reuptake inhibitorsen_US
dc.subject.meshVenlafaxine hydrochlorideen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusBilateral; Angle Closure Glaucoma; Topiramateen_US
dc.subject.wosOphthalmologyen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.titleHow does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?en_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: